Elenbecestat
- Generic Name
- Elenbecestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N5O2S
- CAS Number
- 1388651-30-6
- Unique Ingredient Identifier
- RXJ96XL94H
- Background
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
- Associated Conditions
- -
- Associated Therapies
- -
Remembering Bruce Albala, 70, Leader in BACE Inhibitor Development
Bruce Albala, a key figure in Alzheimer's disease drug development, passed away during his 40th wedding anniversary in Greece. Known for his work on β-secretase inhibitors, Albala led Eisai's BACE program, guiding elenbecestat through Phase 3 trials. Despite elenbecestat's limited success, Albala's pragmatic approach and advocacy for safer BACE inhibitor doses were highly regarded. He transitioned to academia in 2019, focusing on improving AD clinical trial efficiency.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath